Cabaletta Bio (CABA) EBIT (2018 - 2025)

Cabaletta Bio's EBIT history runs 8 years deep, the most recent figure standing at -$42.6 million for Q4 2025.

• In Q4 2025, EBIT fell 26.12% year-over-year to -$42.6 million; the TTM figure through Dec 2025 stood at -$172.2 million (down 37.64% YoY), while the FY2025 annual figure was -$172.2 million, down 37.64% from the prior year.
• EBIT was -$42.6 million for Q4 2025 at Cabaletta Bio, up from -$46.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$9.7 million in Q1 2021 to a low of -$46.6 million in Q3 2025.
• Historically, EBIT has averaged -$23.6 million across 5 years, with a median of -$17.8 million in 2023.
• The sharpest annual moves came in 2022 and 2024: EBIT retreated 1.86% in 2022, then plunged 90.55% in 2024.
• A 5-year view of EBIT shows it stood at -$13.9 million in 2021, then fell by 17.34% to -$16.3 million in 2022, then slumped by 41.98% to -$23.1 million in 2023, then plunged by 45.96% to -$33.8 million in 2024, then declined by 26.12% to -$42.6 million in 2025.
• The last three EBIT figures came in at -$42.6 million (Q4 2025), -$46.6 million (Q3 2025), and -$45.9 million (Q2 2025), per Business Quant data.